[go: up one dir, main page]

BR0209282A - Antibacterial composition - Google Patents

Antibacterial composition

Info

Publication number
BR0209282A
BR0209282A BR0209282-4A BR0209282A BR0209282A BR 0209282 A BR0209282 A BR 0209282A BR 0209282 A BR0209282 A BR 0209282A BR 0209282 A BR0209282 A BR 0209282A
Authority
BR
Brazil
Prior art keywords
bacterial
antibacterial composition
amino acid
relates
cytoskeleton
Prior art date
Application number
BR0209282-4A
Other languages
Portuguese (pt)
Inventor
Frank Mayer
Original Assignee
Novologix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10129870A external-priority patent/DE10129870A1/en
Application filed by Novologix Gmbh filed Critical Novologix Gmbh
Publication of BR0209282A publication Critical patent/BR0209282A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18Testing for antimicrobial activity of a material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMPOSIçãO ANTIBACTERIANA". A presente invenção refere-se à aplicação de substâncias, que ligam no fator de translação bacteriano EF-Tu, para a inibição da formação de um citoesqueleto em células bacterianas e para a preparação de composições antiacterianas. Além disso, a invenção refere-se a composições bacterianas, que contêm fragmentos das seq³ências de aminoácidos dos domínios 2 e/ou 3 de uma proteína EF-Tu bacteriana com um comprimento de preferentemente 4-20 aminoácidos."ANTIBACTERIAL COMPOSITION". The present invention relates to the application of substances which bind on the bacterial translational factor EF-Tu for inhibiting the formation of a cytoskeleton in bacterial cells and for the preparation of anti-bacterial compositions. Further, the invention relates to bacterial compositions containing fragments of the amino acid sequences of domains 2 and / or 3 of a bacterial EF-Tu protein of preferably 4-20 amino acid length.

BR0209282-4A 2001-04-30 2002-04-22 Antibacterial composition BR0209282A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10121145 2001-04-30
DE10129870A DE10129870A1 (en) 2001-04-30 2001-06-21 Antibacterial
PCT/EP2002/004410 WO2002087554A2 (en) 2001-04-30 2002-04-22 Ef-tu binding agent as antibacterial agent

Publications (1)

Publication Number Publication Date
BR0209282A true BR0209282A (en) 2004-07-27

Family

ID=26009202

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209282-4A BR0209282A (en) 2001-04-30 2002-04-22 Antibacterial composition

Country Status (17)

Country Link
EP (1) EP1397157A2 (en)
JP (1) JP2004534016A (en)
CN (1) CN1298739C (en)
AU (1) AU2002302555B2 (en)
BG (1) BG108399A (en)
BR (1) BR0209282A (en)
CA (1) CA2445995A1 (en)
CZ (1) CZ20033271A3 (en)
EE (1) EE200300530A (en)
HU (1) HUP0401586A3 (en)
IL (1) IL158627A0 (en)
MX (1) MXPA03009954A (en)
NZ (1) NZ529662A (en)
PL (1) PL366836A1 (en)
RU (1) RU2003134636A (en)
SK (1) SK14792003A3 (en)
WO (1) WO2002087554A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10229645A1 (en) * 2002-07-02 2004-05-19 Kuchenreuther, Ulrich, Dr. Cell disruption of bacteria
AU2010278860B2 (en) 2009-07-31 2016-05-26 Thar Pharma, Llc Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
CN105218668B (en) * 2015-10-30 2020-03-24 山东农业大学 EF-Tu protein monoclonal antibody MAb of Brucella malta and its preparation method and application
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466251A1 (en) * 1990-07-10 1992-01-15 Gist-Brocades N.V. Elfamycin-resistant mutants
ATE343642T1 (en) * 1998-01-23 2006-11-15 Biomerieux Bv EF-TU MRNA AS A MARKER FOR VIABLE BACTERIA
US6451556B1 (en) * 1998-12-21 2002-09-17 Smithkline Beecham Corporation EF-Tu

Also Published As

Publication number Publication date
BG108399A (en) 2004-08-31
WO2002087554A3 (en) 2003-01-30
WO2002087554A2 (en) 2002-11-07
HUP0401586A3 (en) 2005-06-28
WO2002087554B1 (en) 2005-01-27
PL366836A1 (en) 2005-02-07
EP1397157A2 (en) 2004-03-17
EE200300530A (en) 2004-04-15
SK14792003A3 (en) 2004-07-07
CN1298739C (en) 2007-02-07
MXPA03009954A (en) 2005-07-25
JP2004534016A (en) 2004-11-11
IL158627A0 (en) 2004-05-12
CN1518455A (en) 2004-08-04
CZ20033271A3 (en) 2004-06-16
HUP0401586A2 (en) 2004-11-29
CA2445995A1 (en) 2002-11-07
AU2002302555B2 (en) 2007-08-23
NZ529662A (en) 2006-08-31
RU2003134636A (en) 2005-04-20

Similar Documents

Publication Publication Date Title
BR9910089A (en) Compositions and antigens of neisseria meningitidis
DE602004022056D1 (en) ANTIBACTERIAL COMPOSITION, ESPECIALLY FOR COMBATING GRAMBEGATIVE BACTERIA, COMPREHENSIVELY A PEPTIDE AND A BENEFICIAL HYDROPHOBIC ANTIBACTERIAL AGENCY
ATE188996T1 (en) DNA SEQUENCES CODING FOR NOVEL GROWTH/DIFERENTATION FACTORS
BR9713404A (en) esters of n- (aryl / heteroarylacetyl) amino acids, pharmaceutical compositions comprising them, and methods for inhibiting the release of beta-amyloid peptide and / or its synthesis by using such compounds.
BRPI0407058A (en) Methods of prophylaxis and treatment of a disease, pharmaceutical composition, and use of a fragment
BR0115427A (en) Compound, pharmaceutical composition, methods for inhibiting the release of beta-amyloid peptide and / or its synthesis, for treating Alzheimer's disease, and for preventing the disease and the progress of Alzheimer's disease, and, use of a compound.
HUP0002322A2 (en) Multivalent vaccine composition with mixed carrier
BRPI9915679B8 (en) compositions and methods to increase bone mineralization
BR0009564A (en) Use of cyp2d6 inhibitors in combination therapies
BRPI0511421A (en) cosmetic and pharmaceutical compositions for treating keratin-containing materials, use of cosmetic compositions, keratin-binding effector molecule, use thereof, and process
BR9914066A (en) Human complement c3-degrading polypeptide from streptococcus pneumoniae
UY24949A1 (en) CALCILITE COMPOUNDS
BR9406689A (en) Defective recombinant adenovirus use of this adenovirus and pharmaceutical composition obtained
DE60233532D1 (en) SYNTHETIC ODE APPLICATIONS BINDING TO PROTEIN PHOSPHATASE 2A
BR0316923A (en) Mitoneet polypeptide of mitochondrial membranes, their modulators and methods for their use
BR0014860A (en) Methods for producing a target molecule in a transgenic animal and purifying the target molecule
BR0209282A (en) Antibacterial composition
DE602004025265D1 (en) NEW PHOSPHAT BINDING PROTEIN, PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF AND USE THEREOF
BRPI0415781A (en) Method for treating diabetes in a patient and pharmaceutical kit
BR9510067A (en) Peptide capable of interacting with the sh3 domain of the antibody gap protein or antibody fragment directed against a polypeptide nucleotide sequence encoding an antisense nucleic acid polypeptide capable of at least partially inhibiting the production of polypeptides its use pharmaceutical composition and use of an antibody or antibody fragment
BR0208786A (en) Method for identification of intracellular bacterial proteins
BR9714049A (en) Imidazopyridazines
BR0212219A (en) Peptide compounds that selectively bind to p-selectin
BRPI9916549B8 (en) PHARMACEUTICAL COMPOSITION, PROTEIN, POLYNUCLEOTIDE
EP1073623A4 (en) Substituted amino acids as erythropoietin mimetics

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]